Department of General Surgery, Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, The Sparkfire Scientific Research Group of Nanjing Medical University, Nanjing, China.
Reproductive Medicine Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
J Cell Physiol. 2019 Aug;234(8):12122-12132. doi: 10.1002/jcp.28048. Epub 2019 Jan 15.
Hepatocellular carcinoma (HCC) is one of the most common malignancies and is a serious threat to people's health worldwide. The prognosis of advanced HCC is dim if left untreated. In the clinic, the treatment options for advanced HCC include surgery, radiotherapy, transcatheter arterial chemoembolization, and so forth. In recent years, molecular targeted therapy and immunotherapy have also made great progress, bringing new hope to patients with advanced HCC. In this study, therapeutic advances, current dilemma, and future directions of advanced HCC are reviewed, which might serve as a summary for clinicians and may stimulate future research.
肝细胞癌（HCC）是最常见的恶性肿瘤之一，也是全球范围内严重威胁人类健康的疾病。如果不加以治疗，晚期 HCC 的预后较差。在临床上，晚期 HCC 的治疗选择包括手术、放疗、经导管动脉化疗栓塞等。近年来，分子靶向治疗和免疫治疗也取得了很大进展，为晚期 HCC 患者带来了新的希望。本研究对晚期 HCC 的治疗进展、当前困境和未来方向进行了综述，可为临床医生提供参考，并可能激发未来的研究。
